US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

32.19

-0.2651-0.82%

Volume:39

Turnover:1K

Market Cap:643.72K

PE:- -

High:32.19

Open:32.45

Low:32.19

Close:32.45

52wk High:35.56

52wk Low:25.40

Shares:20.00K

Float Shares:20.00K

Volume Ratio:0.11

T/O Rate:0.19%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating

Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027

Aetna Has About 70% of Medicare Advantage Members in Four-Star-or-Better 2027 Plans, CVS Health Says

Alignment Healthcare Slides After a Medicare Advantage Contract Gets 3.5-Star Rating

Clover Health up over 8% after-hours following CMS Star Ratings update

Medicare Open Enrollment Starts Next Week. Why It's Really Important to Shop This Year.

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Humana (HUM), Why Is It Back In The Spotlight?

Simply Wall St.

Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

EBR Systems advances FDA approval process for new WiSE manufacturing site

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

Ultragenyx price target raised to $35 from $32 at Barclays

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/XLVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","market":"US","secType":"STK","nameCN":"Corgi U.S. Healthcare 2x Daily ETF","latestPrice":32.1861,"timestamp":1791489600000,"preClose":32.4512,"halted":0,"volume":39,"delay":0,"changeRate":-0.00816918942905029,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.2651,"latestTime":"10-09 05:59:53 EDT","open":32.4512,"high":32.1861,"low":32.1861,"amount":1254,"amplitude":0,"askPrice":51.17,"askSize":100,"bidPrice":12.95,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":32.1861,"nav":32.43,"aum":648600,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.4512,"preClose":32.1861,"latestTime":"16:10 EDT","volume":6,"amount":193.1166,"timestamp":1791490204592,"change":0.2651,"changeRate":0.008236,"amplitude":0},"volumeRatio":0.10557666502318991},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.10557666502318991,"shares":20000,"dividePrice":0,"high":32.1861,"amplitude":0,"preClose":32.4512,"low":32.1861,"week52Low":25.3968,"pbRate":"--","week52High":35.56,"institutionHeld":0,"latestPrice":32.1861,"eps":0,"divideRate":0,"volume":39,"delay":0,"ttmEps":0,"open":32.4512,"prevYearClose":25.46,"prevWeekClose":31.5253,"prevMonthClose":32.5588,"prevQuarterClose":32.5588,"fiveDayClose":31.559,"twentyDayClose":31.2748,"sixtyDayClose":29.0546},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674855158","title":"Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2674855158","media":"Dow Jones","labels":["dataReport"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2674855158?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:45","pubTimestamp":1791499500,"startTime":"0","endTime":"0","summary":"Humana stock gained 13% in after hours trading Thursday after the federal government released new ratings data on Medicare Advantage plans, showing that Humana achieved a four-star rating on a key con","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUM","IHF","LNGR","IYH","IEHS","XHS","XLVX","UNHU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674885693","title":"Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885693?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:45","pubTimestamp":1791499500,"startTime":"0","endTime":"0","summary":"Star ratings support Clover’s continued ability to offer market-leading and low out-of-pocket costs for membersWILMINGTON, Del., Oct.  08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Na","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377770/0/en/clover-health-medicare-advantage-ppo-plans-earn-5-star-rating-for-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHF","IYH","XLVX","UNHU","XHS","IEHS","LNGR","HUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674488588","title":"Aetna Has About 70% of Medicare Advantage Members in Four-Star-or-Better 2027 Plans, CVS Health Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674488588","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674488588?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:34","pubTimestamp":1791498840,"startTime":"0","endTime":"0","summary":"CVS Health's health-insurance company Aetna said that more 69% of its Medicare Advantage members are in 2027 plans rated four stars or higher by the government.The Centers for Medicare & Medicaid Services evaluates insurance plans based on a five-star rating system every year.Aetna received five stars for its care for older adults medication review and 4.03 stars for its care for older adults functional status assessment, CVS Health said.On plan all-cause readmissions, which tracks the percentage of patient hospital stays followed by an unplanned readmission, received 4.77 stars, the company said.Aetna has above four-star ratings for its rate of complaints about the drug plan, customer service and rating of healthcare quality, CVS Health said.Shares of the company slipped 2.7%, to $85.47, after hours Thursday after closing about flat, at $87.80.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LNGR","LU0256863811.USD","UNHG","LU0417517546.SGD","LU0170899867.USD","XLVX","LU1059921491.USD","LU0208291251.USD","LU2125909247.SGD","XHS","LU1093756168.USD","LU0238689110.USD","BK4585","BK4533","IE00BSNM7G36.USD","LU0348723411.USD","LU0390134368.USD","BK4550","LU1093756325.SGD","LU1236620834.HKD","RTH","IE00B19Z3B42.SGD","IHF","LU0061475181.USD","UN","UNHU","BK4196","FXH","BK4154","SG9999014013.SGD","HUM","LU0072461881.USD","BK4588","LU0070302665.USD","IE00BZ1G4Q59.USD","BK4504","IYH","LU0859254822.USD","CVS","LU0266013472.USD","AET","SG9999014021.USD","IE0002270589.USD","LU1923622614.USD","LU0432979614.USD","LU2433249047.HKD","LU0211331839.USD","UNHW","IEHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883515","title":"Alignment Healthcare Slides After a Medicare Advantage Contract Gets 3.5-Star Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883515","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883515?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:42","pubTimestamp":1791495720,"startTime":"0","endTime":"0","summary":"Shares of Alignment Healthcare fell after one of its 2027 Medicare Advantage contracts received a 3.5-star rating from the Centers for Medicare & Medicaid Services, according to the company.The stock slipped 21%, to $6.90, after-hours Thursday. It closed 1.9% higher, at $8.71, but has fallen 56% this year.The 3.5-star rating, part of CMS's annual ratings of Medicare Advantage plans, was given to the company's California H3815 HMO contract.\"Alignment believes the rating does not accurately reflect the contract's longstanding performance on evidence-based measures of quality, clinical outcomes and member experience,\" the company said.Dawn Maroney, the chief executive officer of Alignment Health Plan, said the company supports measuring the quality of health plans but called into question CMS's methodology.\"We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,\" she said.\"At the same time, our strategy remains un","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","IEHS","UNHU","LNGR","XLVX","XHS","HUM","IHF","ALHC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674279888","title":"Clover Health up over 8% after-hours following CMS Star Ratings update","url":"https://stock-news.laohu8.com/highlight/detail?id=2674279888","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674279888?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:15","pubTimestamp":1791494115,"startTime":"0","endTime":"0","summary":"Shares of Clover Health (CLOV) are up 8.5% after-hours at $4.97 after the release of 2027 Medicare Advantage and Part D Star Ratings that boosted C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clover-health-up-over-8-after-hours-following-cms-star-ratings-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clover-health-up-over-8-after-hours-following-cms-star-ratings-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEHS","IHF","FXH","SG9999014005.SGD","BK4566","UNHW","LU0348723411.USD","LU1093756168.USD","LU0170899867.USD","LU0238689110.USD","LU0266013472.USD","BK4585","BK4154","HUM","LU0070302665.USD","UN","UNHU","CLOV","LU0417517546.SGD","UNHG","XHS","SG9999014013.SGD","XLVX","LU1983260115.SGD","BK4547","LU0208291251.USD","SG9999014021.USD","LU1093756325.SGD","LU0256863811.USD","BK4588","BK4533","IYH","LU0390134368.USD","LNGR","LU0211331839.USD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702989","title":"Medicare Open Enrollment Starts Next Week. Why It's Really Important to Shop This Year.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702989?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:00","pubTimestamp":1791442800,"startTime":"0","endTime":"0","summary":"Medicare's annual open enrollment period begins Oct. 15, and beneficiaries may find fewer options as carriers scale back their plans.Market contractions cut across Medicare Advantage, the privately ru","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LU0211331839.USD","LU0390134368.USD","LU0070302665.USD","LU1093756168.USD","SG9999014005.SGD","LU0256863811.USD","SG9999014013.SGD","HUM","LU0348723411.USD","SG9999014021.USD","XHS","BK4154","LU0170899867.USD","UNHW","LU0417517546.SGD","BK4533","LU0266013472.USD","IEHS","UNHG","XLVX","LU1093756325.SGD","FXH","LU0320765489.SGD","IHF","UNHU","LU0238689110.USD","BK4585","BK4566","LU0208291251.USD","UN","BK4588","IYH","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","LU0320765489.SGD","LFSC","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BBP","BK4578","SYNB","TECB","IE00BFTCPJ56.SGD","PINK","BMED","IBB","BK4585","XLVX","MEDX","PSCH","IE0002141913.USD","LU0070302665.USD","BK4588","IE00B4R5TH58.HKD","IDNA","IE0009355771.USD","NVS","MEDI","GDOC","BK4007","IYH","NVIB","LU0211331839.USD","GNMX","FRTY","MRNX","LABU","TBXU","IE00BJT1NW94.SGD","MRNY","BK4532","RSPH","PPH","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","RSPH","LU1244550221.USD","MEDI","BBP","BK4581","IE00B3S45H60.SGD","IAI","LU0267386448.USD","LU0795875169.SGD","SYNB","TBXU","LU1064131342.USD","IYH","LU0390134368.USD","BMED","IE00BZ1G4Q59.USD","KBWB","LU2023251221.USD","IDNA","GNMX","GDOC","LU2264538146.SGD","FRTY","LU2487616109.SGD","MRNY","PSCH","LABU","BK4504","LU0210528500.USD","LU1720051017.SGD","TECB","XLVX","LU0528227936.USD","BK4585","NVIB","LU0912757837.SGD","LU1720051108.HKD","MRNX","IBB","LU1668664300.SGD","LU2357305700.SGD","SD","LFSC","LU2028103732.USD","LU1791710582.SGD","LU1989772840.SGD","LU2089284900.SGD","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672779757","title":"Humana (HUM), Why Is It Back In The Spotlight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672779757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672779757?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:27","pubTimestamp":1790918866,"startTime":"0","endTime":"0","summary":"Humana (HUM) just outlined its 2027 Medicare Advantage lineup, highlighting $0 in-network primary care and labs, dental, vision and hearing benefits, and an expanded footprint for chronic condition special needs plans.\nHumana’s latest Medicare Advantage refresh lands after a strong run, with the share price up 43.56% year to date and a 1 year total shareholder return of 49.57%, although the 3 year and 5 year total shareholder returns remain in decline. This suggests recent momentum is...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IEHS","HUM","BK7500","BK4585","SG9999014013.SGD","SG9999014021.USD","UNHW","IYH","BK4588","LU0256863811.USD","LU0390134368.USD","LU0208291251.USD","BK4533","BK4154","XHS","HUM.AU","LU1093756325.SGD","LU0266013472.USD","LU0417517546.SGD","LNGR","LU0238689110.USD","UNHG","SG9999014005.SGD","LU0070302665.USD","IHF","FXH","LU0170899867.USD","LU0320765489.SGD","BK4566","LU1983260115.SGD","LU0211331839.USD","UN","XLVX","BK7093","LU0348723411.USD","UNHU","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754056","title":"Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754056","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754056?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856000,"startTime":"0","endTime":"0","summary":"Clover’s portfolio combines high-choice PPO access and meaningful member benefits with a Clover Assistant-powered care modelWILMINGTON, Del., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investmen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372826/0/en/clover-health-s-2027-medicare-advantage-plans-emphasize-ppo-choice-preventive-care-and-member-value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNHU","UNHW","CGCV","LNGR","XLVX","IE00BN29S564.USD","IE00BJJMRY28.SGD","IHF","FNCL","FDFF","STBQ","LU2552382058.USD","XLF","IXJ","LU0950375773.USD","CLOV","IYH","LU0345770993.USD","CHH","UNHG","IE00B4JS1V06.HKD","BK4559","IE000F7OJYX1.SGD","LU0320765059.SGD","LU0316494557.USD","MA","UYG","XHS","VHT","HUM","LU0061474960.USD","LU0210536198.USD","IEHS","FXH","LU0868494617.USD","IE00B775H168.HKD","BK4534","LU0210533765.USD","LU0276348264.USD","UN","LU2404859667.USD","IPAY","NOBL","LATR","IYG","TCAF","LU2552382132.HKD","LU2462157665.USD","CA","VFH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672816387","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672816387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672816387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 02:03","pubTimestamp":1790791380,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","FXH","LU0208291251.USD","BK4585","XLVX","LU0238689110.USD","IEHS","LU0348723411.USD","SG9999014013.SGD","LU0070302665.USD","HUM","LU0256863811.USD","LU0170899867.USD","LU0417517546.SGD","LU1983260115.SGD","LU0320765489.SGD","LU0211331839.USD","LU1093756168.USD","UN","IYH","LU0266013472.USD","LU1093756325.SGD","BK4154","XHS","IHF","SG9999014021.USD","UNHU","LNGR","BK4533","UNHG","BK4588","SG9999014005.SGD","LU0390134368.USD","UNHW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671431772","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2671431772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671431772?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:17","pubTimestamp":1790695020,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","UN","LU0256863811.USD","LU0348723411.USD","LU1983260115.SGD","LNGR","LU0320765489.SGD","IHF","LU1093756325.SGD","XLVX","LU0211331839.USD","SG9999014013.SGD","LU0266013472.USD","IYH","UNHU","LU1093756168.USD","BK4588","LU0417517546.SGD","SG9999014005.SGD","UNHG","IEHS","LU0170899867.USD","XHS","HUM","BK4154","LU0208291251.USD","LU0238689110.USD","LU0390134368.USD","FXH","LU0070302665.USD","SG9999014021.USD","BK4533","BK4585","UNHW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MRNY","PINK","IYH","TEVA","XLVX","SYNB","NVIB","RSPH","LFSC","BK4559","MEDI","GDOC","BK4557","BK4566","BK4588","BBP","BMED","GNMX","BK4007","IBB","LU2324357040.USD","IDNA","IEIH","PSCH","BK4584","FRTY","LABU","LU1983299246.USD","TECB","TBXU","BK4596","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GDOC","TBPH","FRTY","BK4585","XLVX","LFSC","BMED","MRNY","LABU","TBXU","TECB","SYNB","BK4588","NVIB","PINK","PSCH","BBP","IYH","GNMX","MEDI","IBB","IEIH","MRNX","RSPH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","LABU","FRTY","LFSC","IYH","PSCH","BBP","SYNB","IBB","XLVX","BK4588","TBXU","PINK","MEDI","BK4585","TECB","BMED","NVIB","GNMX","MRNX","RSPH","IEIH","GDOC","EES","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","GNMX","RSPH","IEIH","MESO","FRTY","MRNX","GDOC","TBXU","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147769","title":"Lucid Diagnostics advances Medicare reimbursement and coding infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147769","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147769?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:29","pubTimestamp":1790083753,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On September 22, 2026, Lucid Diagnostics announced key advances in payment, billing and codin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0433182093.SGD","IE00B775SV38.USD","BK4082","LNGR","LU0868494617.USD","REZ","LU1150488135.SGD","BK4099","XLVI","MHIP","DVXV","BMED","IEHS","LU1084165304.USD","PINK","TRUH","LU0310799852.SGD","LCID","XLVX","HTEC","MHIG","IE00B3S45H60.SGD","FHLC","IYH","BK4585","LUCD","BK4551","CURE","LU0708994859.HKD","PSCH","SG9999014013.SGD","AGNG","LCDL","JHMH","FXH","LU0203347892.USD","PTH","XHE","RSPH","LU0310800379.SGD","TMED","RXD","LCIZ","LU1267930490.SGD","BK4588","MEDI","IHI","SG9999014039.USD","IHF","HCA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IBB","IYH","NVIB","SYNB","LABU","LFSC","IEIH","TECB","GDOC","GNMX","BMED","PSCH","TBXU","BK4588","MRNY","FRTY","BBP","MEDI","BK4585","IDNA","RARE","RSPH","BK4139","XLVX","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","GDOC","PSCH","SYNB","PINK","MRNY","NVIB","BK4007","BMED","LABU","LFSC","IEIH","TBXU","IBB","IYH","IDNA","BK4588","GNMX","MRNX","BK4585","RSPH","FRTY","MEDI","TECB","AMRX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABEO","PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","GDOC","MRNY","BMED","BBP","LFSC","IBB","BK4139","TBXU","IYH","RARE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":76,"code":"91000000","status":"200"}]}}